Emilia Qomi Ekenel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Emilia Qomi Ekenel has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Tugba Semerci Sevimli
Eskisehir Osmangazi University
5 shared publications - Ayla Eker Sariboyaci
Eskisehir Osmangazi University
4 shared publications - Onur Uysal
Eskisehir Osmangazi University
4 shared publications - Sibel Gunes
Eskişehir Osmangazi Üniversitesi, Hücresel Tedavi ve Kök Hücre Üretim, Uygulama ve Araştırma Merkezi (ESTEM)
4 shared publications - Huseyin Avci
Cellular Therapy and Stem Cell Production Application and Research Centre, ESTEM Eskisehir Osmangazi University Eskisehir Turkey
3 shared publications - Merve Nur Soykan
Eskisehir Osmangazi University
3 shared publications
Latest Publications
- Open Access
- 27 April 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (5) , e71799
Development of a High‐Sensitivity Electrochemical Biosensor for Domoic Acid and Its Cellular Impact on Human Stem and Neuron‐Like Cells
Domoic acid (DA) is an important environmental neurotoxin produced by certain types of marine algae and can accumulate in seafood such as anchovies, sardines, and mussels, which are considered healthy and widely consumed globally. One of the most important issues to consider is taking necessary measures to prevent water and marine pollution and conducting proper safety controls before consuming seafood. This study aimed to develop a high‐sensitivity electrochemical biosensor system for detecting DA in seafood, aiding marine pollution monitoring. Additionally, the cytotoxicity of DA at the highest Food & Drug Administration (FDA)‐permitted concentration and the concentrations determined in this study was examined on human cells. Gene expression related to cytotoxic response, DNA repair, and neurotoxicity was analyzed using amniotic fluid‐derived mesenchymal stem cells (hAF‐MSCs) and the human neuroblastoma cell line (SH‐SY5Y) as neuron‐like cell models. DA did not significantly affect the viability of hAF‐MSCs or SH‐SY5Y cells at 48‐h exposure but slightly reduced viability at 100 μg/mL compared to the control group. DA activated the glutamate receptor in hAF‐MSCs but not in SH‐SY5Y cells. It also reduced DNA repair capacity in hAF‐MSCs, though effects on viability and proliferation likely did not manifest within 48 h. There was no change in gene expression at 75 ng/mL of DA, which indicated the tolerable daily intake set by the FDA. The SH‐SY5Y cells exhibited resistance against DA, indicating enhanced their DNA repair to prevent themselves against apoptosis and cell death. It is also supported by the upregulation of DNA repair‐related genes and the membrane transporter gene ABCG2.
- 27 April 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (5) , e71799
Open AccessDevelopment of a High‐Sensitivity Electrochemical Biosensor for Domoic Acid and Its Cellular Impact on Human Stem and Neuron‐Like Cells
Domoic acid (DA) is an important environmental neurotoxin produced by certain types of marine algae and can accumulate in seafood such as anchovies, sardines, and mussels, which are considered healthy and widely consumed globally. One of the most important issues to consider is taking necessary measures to prevent water and marine pollution and conducting proper safety controls before consuming seafood. This study aimed to develop a high‐sensitivity electrochemical biosensor system for detecting DA in seafood, aiding marine pollution monitoring. Additionally, the cytotoxicity of DA at the highest Food & Drug Administration (FDA)‐permitted concentration and the concentrations determined in this study was examined on human cells. Gene expression related to cytotoxic response, DNA repair, and neurotoxicity was analyzed using amniotic fluid‐derived mesenchymal stem cells (hAF‐MSCs) and the human neuroblastoma cell line (SH‐SY5Y) as neuron‐like cell models. DA did not significantly affect the viability of hAF‐MSCs or SH‐SY5Y cells at 48‐h exposure but slightly reduced viability at 100 μg/mL compared to the control group. DA activated the glutamate receptor in hAF‐MSCs but not in SH‐SY5Y cells. It also reduced DNA repair capacity in hAF‐MSCs, though effects on viability and proliferation likely did not manifest within 48 h. There was no change in gene expression at 75 ng/mL of DA, which indicated the tolerable daily intake set by the FDA. The SH‐SY5Y cells exhibited resistance against DA, indicating enhanced their DNA repair to prevent themselves against apoptosis and cell death. It is also supported by the upregulation of DNA repair‐related genes and the membrane transporter gene ABCG2.
- 27 January 2026
- Published by Anadolu Universitesi Bilim ve Teknoloji Dergisi C : Yasam Bilimleri ve Biyoteknoloji in Eskişehir Teknik Üniversitesi Bilim ve Teknoloji Dergisi - C Yaşam Bilimleri ve Biyoteknoloji
- Vol. 15 (1) , 32-45
INTEGRATED TRANSCRIPTOMIC PROFILING OF THE Candida albicans RESPONSE TO THE SYNERGISTIC INTERACTION BETWEEN ATOMOXETINE AND FLUCONAZOLE
Candida species are notorious opportunistic pathogens that can cause severe infections, especially in immunocompromised and medically vulnerable patients. Despite the availability of various antifungal drugs, their efficacy is often limited by drug toxicity and antifungal resistance. Therefore, repurposing existing clinically approved drugs is a promising approach to addressing this challenge. In this study, we investigated the potential synergistic effects of combining the antidepressant atomoxetine (ATMX) with the antifungal agent fluconazole (FLC) against Candida albicans. Our results demonstrated that ATMX (31.25 μg/mL) and FLC (1.95 μg/mL) exhibited a trend toward synergistic activity C. albicans. We performed RNA-Seq analysis to investigate the transcriptional response of C. albicans treated with ATMX-FLC combination. Our analysis indicated that the combination has a significant impact on ribosome biogenesis, secondary metabolite biosynthesis, and metabolic pathways. Overall, our findings highlight the potential of repurposing clinically approved drugs as a novel therapeutic strategy for the treatment of Candida infections, which continue to pose a significant global public health challenge.
- 27 January 2026
- Published by Anadolu Universitesi Bilim ve Teknoloji Dergisi C : Yasam Bilimleri ve Biyoteknoloji in Eskişehir Teknik Üniversitesi Bilim ve Teknoloji Dergisi - C Yaşam Bilimleri ve Biyoteknoloji
- Vol. 15 (1) , 32-45
INTEGRATED TRANSCRIPTOMIC PROFILING OF THE Candida albicans RESPONSE TO THE SYNERGISTIC INTERACTION BETWEEN ATOMOXETINE AND FLUCONAZOLE
Candida species are notorious opportunistic pathogens that can cause severe infections, especially in immunocompromised and medically vulnerable patients. Despite the availability of various antifungal drugs, their efficacy is often limited by drug toxicity and antifungal resistance. Therefore, repurposing existing clinically approved drugs is a promising approach to addressing this challenge. In this study, we investigated the potential synergistic effects of combining the antidepressant atomoxetine (ATMX) with the antifungal agent fluconazole (FLC) against Candida albicans. Our results demonstrated that ATMX (31.25 μg/mL) and FLC (1.95 μg/mL) exhibited a trend toward synergistic activity C. albicans. We performed RNA-Seq analysis to investigate the transcriptional response of C. albicans treated with ATMX-FLC combination. Our analysis indicated that the combination has a significant impact on ribosome biogenesis, secondary metabolite biosynthesis, and metabolic pathways. Overall, our findings highlight the potential of repurposing clinically approved drugs as a novel therapeutic strategy for the treatment of Candida infections, which continue to pose a significant global public health challenge.
- Open Access
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S1) , e105818
Investigation of Alzheimer's Disease‐Associated effect of SPOCK1 Protein on Apoptosis in Nerve Cells
Background: SPOCK1, a member of the SPARC family, is highly expressed in breast, lung, prostate, and liver cancer. Various studies have demonstrated that SPARC family proteins play a crucial role in the development and diseases of the central nervous system (CNS). However, the role of SPOCK1, a member of the SPARC family, in CNS diseases—particularly Alzheimer's disease—remains unknown. Previously, we have reported an association between SPOCK1 variants and LOAD in a genome‐wide association studies (GWAS) meta‐analysis. Based on our observation and the recent literature on SPOCK1, we explored the role of SPOCK1 in different neuronal cells to understand its possible function in Alzheimer's pathogenesis. Methods: Human astroglia (SVGp12), microglial (HMC3), and neuroblastoma (SH‐SY5Y) cell lines expressing fluorescently tagged SPOCK1 and un‐tagged SPOCK1 were used to investigate the expression and localization of SPOCK1 via immunocytochemistry (ICC) and confocal image analysis. It is well known that Alzheimer's disease is associated with death mechanisms in nerve cells. To investigate the molecular basis of Alzheimer's disease based on the possible unpredicted interactions and roles of SPOCK1 protein in mitochondrial cell death, SPOCK1 gene silencing and over‐expression effects on apoptosis were detected via TUNEL assay in human astroglia (SVGp12), microglial (HMC3), and neuroblastoma (SH‐SY5Y) cell lines. Results: Our results based on immunocytochemistry (ICC) and confocal image analysis with various organelle markers showed for the first time that SPOCK1 is localized at the mitochondria of all the microglial, neuroblastoma, and astroglia cells. Moreover, apoptosis was detected in SPOCK1 over‐expressed astrocyte cells. However in SPOCK1 over‐expressing neuroblastoma cells, proliferaiton is observed, and when SPOCK1 was silenced, apoptotic cells were decreased. In microglial cells, no significant change was observed when SPOCK1 was over‐expressed or silenced. Conclusions: For the first time we have shown localization of SPOCK1 in mitochondria in astroglia, microglial, and neuroblastoma cell lines, and studied SPOCK1's effect on cell death in these cell lines. The SPOCK1 overexpression in astrocytes increased apoptosis, highlighting its potential role in cell death. Overall our findings suggest a potantial role for SPOCK1 in Alzheimer's etiology and introducing it as a novel molecule in neurodegenerative diseases.
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S1) , e105818
Open AccessInvestigation of Alzheimer's Disease‐Associated effect of SPOCK1 Protein on Apoptosis in Nerve Cells
Background: SPOCK1, a member of the SPARC family, is highly expressed in breast, lung, prostate, and liver cancer. Various studies have demonstrated that SPARC family proteins play a crucial role in the development and diseases of the central nervous system (CNS). However, the role of SPOCK1, a member of the SPARC family, in CNS diseases—particularly Alzheimer's disease—remains unknown. Previously, we have reported an association between SPOCK1 variants and LOAD in a genome‐wide association studies (GWAS) meta‐analysis. Based on our observation and the recent literature on SPOCK1, we explored the role of SPOCK1 in different neuronal cells to understand its possible function in Alzheimer's pathogenesis. Methods: Human astroglia (SVGp12), microglial (HMC3), and neuroblastoma (SH‐SY5Y) cell lines expressing fluorescently tagged SPOCK1 and un‐tagged SPOCK1 were used to investigate the expression and localization of SPOCK1 via immunocytochemistry (ICC) and confocal image analysis. It is well known that Alzheimer's disease is associated with death mechanisms in nerve cells. To investigate the molecular basis of Alzheimer's disease based on the possible unpredicted interactions and roles of SPOCK1 protein in mitochondrial cell death, SPOCK1 gene silencing and over‐expression effects on apoptosis were detected via TUNEL assay in human astroglia (SVGp12), microglial (HMC3), and neuroblastoma (SH‐SY5Y) cell lines. Results: Our results based on immunocytochemistry (ICC) and confocal image analysis with various organelle markers showed for the first time that SPOCK1 is localized at the mitochondria of all the microglial, neuroblastoma, and astroglia cells. Moreover, apoptosis was detected in SPOCK1 over‐expressed astrocyte cells. However in SPOCK1 over‐expressing neuroblastoma cells, proliferaiton is observed, and when SPOCK1 was silenced, apoptotic cells were decreased. In microglial cells, no significant change was observed when SPOCK1 was over‐expressed or silenced. Conclusions: For the first time we have shown localization of SPOCK1 in mitochondria in astroglia, microglial, and neuroblastoma cell lines, and studied SPOCK1's effect on cell death in these cell lines. The SPOCK1 overexpression in astrocytes increased apoptosis, highlighting its potential role in cell death. Overall our findings suggest a potantial role for SPOCK1 in Alzheimer's etiology and introducing it as a novel molecule in neurodegenerative diseases.
- 27 November 2024
- Published by Springer Nature in Cytotechnology
- Vol. 77 (1) , 8
Synovial fluid mesenchymal stem cell-derived microRNA-127-5p can modulate transforming growth factor-β signaling after in vitro chondrogenic induction
MicroRNA profiling in human cartilage is necessary for chondrogenesis. The study aimed to compare microRNA 127-5p (miR-127-5p) and TGF-β signaling pathway gene expressions of human adipose tissue-derived mesenchymal stem cells (hAT-MSCs) and synovial fluid-derived stem cells (hSF-MSCs) after induced chondrogenesis. MSCs induced into chondrogenic differentiation. Alcian Blue and Safranin O staining were performed to determine chondrogenic differentiation. The RT-qPCR determined the expression levels of miR-127-5p and TGF-β signaling pathway genes. miR-127-5p expression was significantly higher in chondrogenic differentiated hSF-MSCs (dhSF-MSCs) (p < 0.05). TGF-β, SMAD2, and SMAD3 expressions were substantially higher in dhSF-MSCs (all p < 0.001), while SMAD4, and ACAN expressions were downregulated (all p < 0.001). No difference was detected between COL1A2 expression levels. This study suggests that miR-127-5p derived from hSF-MSCs may regulate chondrogenesis, thereby inducing the TGF-β pathway activation, and also presents, for the first time, a comparative analysis of the expression of miR-127-5p and the TGF-β signaling pathway genes of hSF-MSCs and hAT-MSCs concerning differences in chondrogenic potential. Graphical abstract
- 27 November 2024
- Published by Springer Nature in Cytotechnology
- Vol. 77 (1) , 8
Synovial fluid mesenchymal stem cell-derived microRNA-127-5p can modulate transforming growth factor-β signaling after in vitro chondrogenic induction
MicroRNA profiling in human cartilage is necessary for chondrogenesis. The study aimed to compare microRNA 127-5p (miR-127-5p) and TGF-β signaling pathway gene expressions of human adipose tissue-derived mesenchymal stem cells (hAT-MSCs) and synovial fluid-derived stem cells (hSF-MSCs) after induced chondrogenesis. MSCs induced into chondrogenic differentiation. Alcian Blue and Safranin O staining were performed to determine chondrogenic differentiation. The RT-qPCR determined the expression levels of miR-127-5p and TGF-β signaling pathway genes. miR-127-5p expression was significantly higher in chondrogenic differentiated hSF-MSCs (dhSF-MSCs) (p < 0.05). TGF-β, SMAD2, and SMAD3 expressions were substantially higher in dhSF-MSCs (all p < 0.001), while SMAD4, and ACAN expressions were downregulated (all p < 0.001). No difference was detected between COL1A2 expression levels. This study suggests that miR-127-5p derived from hSF-MSCs may regulate chondrogenesis, thereby inducing the TGF-β pathway activation, and also presents, for the first time, a comparative analysis of the expression of miR-127-5p and the TGF-β signaling pathway genes of hSF-MSCs and hAT-MSCs concerning differences in chondrogenic potential. Graphical abstract
- Open Access
- 1 July 2024
- Published by Bentham Science Publishers Ltd. in Current Molecular Medicine
- Vol. 24 (7) , 906-919
Stem Cell-Based or Cell-Free Gene Therapy in Chondrocyte Regeneration: Synovial Fluid-Derived Mesenchymal Stem Cell Exosomes
Background: Cartilage injuries are currently the most prevalent joint disease. Previous studies have emphasized the use of stem cells as the effective treatment for regenerating cartilage damage. Objective: In this study, considering the difficulties of the cellular therapy method, it was hypothesized that human synovial fluid-derived mesenchymal stem cell (hSFMSC) exosomes as a SC source could be used to treat these injuries as a safer and cell-free therapeutic alternative procedure due to its direct relevance to cartilage regeneration. Moreover, this study aimed to determine the miRNA and target genes required for the formation of SC treatment combined with gene therapy in order to reveal the mechanism of cartilage regeneration and increase its effectiveness. Methods: MSCs were characterized by flow cytometry, and immunocytochemical and differentiation analyses were done. To characterize functionally isolated exosomes, in vitro uptake analysis was performed. RT-qPCR was used to examine in terms of the advantages of cellular and cell-free therapy, mature human chondroblasts derived by differentiation from hSF-MSCs and human chondrocyte profiles were compared in order to demonstrate the above profile of hSF-MSCs and exosomes isolated from them, and the effectiveness of SC therapy in repairing cartilage damage. Results: According to our findings, the expression level of hsa-miR-155-5p was found to be considerably higher in chondrocytes differentiated from human synovial fluid MSCs than in mature human chondrocytes. These findings were also supported by the TGF-signalling pathway and chondrogenesis marker genes. Conclusion: It was concluded that hSF-MSCs and exosomes can be used in the treatment of cartilage damage, and hsa-miR-155-5p can be used as a target miRNA in a new gene therapy approach because it increases the therapeutic effect on cartilage damage.
- 1 July 2024
- Published by Bentham Science Publishers Ltd. in Current Molecular Medicine
- Vol. 24 (7) , 906-919
Open AccessStem Cell-Based or Cell-Free Gene Therapy in Chondrocyte Regeneration: Synovial Fluid-Derived Mesenchymal Stem Cell Exosomes
Background: Cartilage injuries are currently the most prevalent joint disease. Previous studies have emphasized the use of stem cells as the effective treatment for regenerating cartilage damage. Objective: In this study, considering the difficulties of the cellular therapy method, it was hypothesized that human synovial fluid-derived mesenchymal stem cell (hSFMSC) exosomes as a SC source could be used to treat these injuries as a safer and cell-free therapeutic alternative procedure due to its direct relevance to cartilage regeneration. Moreover, this study aimed to determine the miRNA and target genes required for the formation of SC treatment combined with gene therapy in order to reveal the mechanism of cartilage regeneration and increase its effectiveness. Methods: MSCs were characterized by flow cytometry, and immunocytochemical and differentiation analyses were done. To characterize functionally isolated exosomes, in vitro uptake analysis was performed. RT-qPCR was used to examine in terms of the advantages of cellular and cell-free therapy, mature human chondroblasts derived by differentiation from hSF-MSCs and human chondrocyte profiles were compared in order to demonstrate the above profile of hSF-MSCs and exosomes isolated from them, and the effectiveness of SC therapy in repairing cartilage damage. Results: According to our findings, the expression level of hsa-miR-155-5p was found to be considerably higher in chondrocytes differentiated from human synovial fluid MSCs than in mature human chondrocytes. These findings were also supported by the TGF-signalling pathway and chondrogenesis marker genes. Conclusion: It was concluded that hSF-MSCs and exosomes can be used in the treatment of cartilage damage, and hsa-miR-155-5p can be used as a target miRNA in a new gene therapy approach because it increases the therapeutic effect on cartilage damage.
- Open Access
- 22 June 2024
- Published by Wiley in Cell Biochemistry and Function
- Vol. 42 (4) , e4079
Establishment, culture and characterization of gemcitabine hydrochloride‐resistant human non‐small cell lung carcinoma cell line derived cancer stem cells
Due to their high expression profile of multi‐drug resistance genes, cancer stem cells (CSCs) are the main source of drug resistance. The aim of this study was to establish a gemcitabine‐hydrochloride‐resistant (rt) human non‐small cell lung cancer (hNSCLC) cell line and their CSC line to be used as disease models in various cancer studies. In the first phase of study, a gemcitabine hydrochloride‐rt hNSCLC line cells was produced by making them rt through periodic exposure to gemcitabine hydrochloride. This acquired gemcitabine‐hydrochloride‐rt hNSCLC cell line was characterized for resistance. Subsequently, a CSC population with a CD326 + CD133 + CD44+ phenotypes was immunoselectively isolated from gemcitabine hydrochloride‐rt hNSCLCs purified from a single cell by colony forming technology. This rt CSC line was characterized for both resistance and stemness. Rt and non‐rt CSCs were analyzed and compared with each other in terms of immunophenotyping the expression profiles of ALDH1, CD90, ABCG2, CD44 and MDR1, which are CSC specific markers, of demonstrating mitotic capacity with growth curve analysis and of their ability to form tumor spheroids in three different 3D cultures. The results of this study demonstrated for the first time the successful generation of both gemcitabine‐hydrochloride‐rt hNSCLC cells and CSCs derived from gemcitabine‐hydrochloride‐rt hNSCLC cells. It was also shown that isolated and characterized rt CSCs could proliferate and form tumor spheres in vitro using three different 3D in vitro techniques. It was shown that the cell surface markers CD326, CD133 and CD44 can serve as an antibody panel for CSCs.
- 22 June 2024
- Published by Wiley in Cell Biochemistry and Function
- Vol. 42 (4) , e4079
Open AccessEstablishment, culture and characterization of gemcitabine hydrochloride‐resistant human non‐small cell lung carcinoma cell line derived cancer stem cells
Due to their high expression profile of multi‐drug resistance genes, cancer stem cells (CSCs) are the main source of drug resistance. The aim of this study was to establish a gemcitabine‐hydrochloride‐resistant (rt) human non‐small cell lung cancer (hNSCLC) cell line and their CSC line to be used as disease models in various cancer studies. In the first phase of study, a gemcitabine hydrochloride‐rt hNSCLC line cells was produced by making them rt through periodic exposure to gemcitabine hydrochloride. This acquired gemcitabine‐hydrochloride‐rt hNSCLC cell line was characterized for resistance. Subsequently, a CSC population with a CD326 + CD133 + CD44+ phenotypes was immunoselectively isolated from gemcitabine hydrochloride‐rt hNSCLCs purified from a single cell by colony forming technology. This rt CSC line was characterized for both resistance and stemness. Rt and non‐rt CSCs were analyzed and compared with each other in terms of immunophenotyping the expression profiles of ALDH1, CD90, ABCG2, CD44 and MDR1, which are CSC specific markers, of demonstrating mitotic capacity with growth curve analysis and of their ability to form tumor spheroids in three different 3D cultures. The results of this study demonstrated for the first time the successful generation of both gemcitabine‐hydrochloride‐rt hNSCLC cells and CSCs derived from gemcitabine‐hydrochloride‐rt hNSCLC cells. It was also shown that isolated and characterized rt CSCs could proliferate and form tumor spheres in vitro using three different 3D in vitro techniques. It was shown that the cell surface markers CD326, CD133 and CD44 can serve as an antibody panel for CSCs.